Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 94.9%

Neg 94.9% Neu 0% Pos 0%

Citizens analyst Brett Knoblauch maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and lowers the price target from $12 to $8.